Ipragliflozin L-Proline is primarily used in the treatment of type 2 diabetes mellitus. It functions as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which helps lower blood glucose levels by preventing the reabsorption of glucose in the kidneys, leading to increased glucose excretion through urine. This mechanism of action not only aids in controlling blood sugar levels but also contributes to weight loss and a reduction in blood pressure, providing additional benefits for patients with diabetes. It is often prescribed as part of a comprehensive diabetes management plan that includes diet, exercise, and other medications. Its use is particularly beneficial for patients who have not achieved adequate glycemic control with other antidiabetic therapies. Regular monitoring of kidney function and blood glucose levels is recommended during treatment to ensure safety and efficacy.